Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer’s diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer’s pathology in the brain. A total of 1189 participants with...
Guardado en:
Autores principales: | Xue-Ning Shen, Yu-Yuan Huang, Shi-Dong Chen, Yu Guo, Lan Tan, Qiang Dong, Jin-Tai Yu, Alzheimer’s Disease Neuroimaging Initiative |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ed93184db7324f0790dfe024c06363af |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease
por: Julia Neitzel, et al.
Publicado: (2021) -
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
por: Nicolai Franzmeier, et al.
Publicado: (2019) -
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Alberto Lleó, et al.
Publicado: (2021) -
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
por: Nicolai Franzmeier, et al.
Publicado: (2020) -
Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease
por: Jacob W. Vogel, et al.
Publicado: (2020)